Country: Canada
Language: English
Source: Health Canada
IPRATROPIUM BROMIDE
TEVA CANADA LIMITED
R03BB01
IPRATROPIUM BROMIDE
250MCG
SOLUTION
IPRATROPIUM BROMIDE 250MCG
INHALATION
10 VIALS X 2 ML
Prescription
ANTIMUSCARINICS ANTISPASMODICS
Active ingredient group (AIG) number: 0115643001; AHFS:
CANCELLED POST MARKET
2018-05-18
PRODUCT MONOGRAPH PR RATIO-IPRATROPIUM UDV (Ipratropium Bromide) 1 mL and 2 mL inhalation solution unit dose vials Each plastic unit dose vial (UDV) contains: 250 mcg of ipratropium bromide in 1 mL 250 mcg of ipratropium bromide in 2 mL 500 mcg of ipratropium bromide in 2 mL BRONCHODILATOR TEVA CANADA LIMITED 30 Novopharm Court Toronto, Ontario Canada, M1B 2K9 Date of Preparation: July 24, 2013 Submission Control No: 166254 _ _ _Product Monograph – ratio-IPRATROPIUM _ _Page 2 of 29 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................5 DRUG INTERACTIONS ..................................................................................................10 DOSAGE AND ADMINISTRATION ..............................................................................10 OVERDOSAGE ................................................................................................................11 ACTION AND CLINICAL PHARMACOLOGY ............................................................11 STORAGE AND STABILITY ..........................................................................................14 SPECIAL HANDLING INSTRUCTIONS .......................................................................14 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................15 PART II: SCIENTIFIC INFORMATION ...............................................................................16 PHARMACEUTIC Read the complete document